FDA Brief

Warning letters Drugs

FDA warning letter to

"David M. Lubeck, M.D./Arbor Centers for EyeCare

High riskIssued Nov 18, 2022Posted Nov 29, 2022Center for Drug Evaluation and Research | CDER

FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.

What happened

FDA inspected the clinical site from April 12 to April 20, 2022, under its Bioresearch Monitoring Program. FDA found that Dr. Lubeck, as sponsor-investigator, began a study of an investigational combination product without submitting or having an IND in effect, and five human subjects were enrolled. FDA also found his May 10, 2022 response inadequate because the IND he later submitted covered a different protocol.

What FDA found

  1. He began a clinical investigation of investigational drugs without submitting an IND.

    21 CFR 312.20(a), 312.20(b)
  2. He did not have an IND in effect before starting the study.

    21 CFR 312.40(a)
  3. The study did not qualify for an IND exemption.

    21 CFR 312.2
  4. He enrolled five subjects and gave study drug without an IND covering the protocol.

    21 CFR 312.40
  5. The IND he later submitted covered a different protocol, not the study he started.

    21 CFR 312.40
  6. His response did not include a corrective action plan for deciding when an IND is required.

    21 CFR 312.2

What FDA wants

Within 15 business days, FDA asks Dr. Lubeck to notify the office in writing of actions taken to prevent similar violations and to provide a corrective action plan for deciding when an IND is required and complying with IND rules.

Who should pay attention

  • sponsor-investigators running investigator-initiated trials
  • IRBs reviewing combination-product studies
  • clinical research sites and study staff

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  2. Blue Horizon International, LLC

    FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.

    High risk
  3. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  4. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk